Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

February 5, 2024

https://www.globenewswire.com/news-release/2024/02/05/2823457/0/en/Ocuphire-Pharma-Announces-Presentation-on-APX3330-at-the-Annual-Angiogenesis-Exudation-and-Degeneration-2024-Conference.html

FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy (DR) were presented at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference, which took place virtually on Saturday, February 3, 2024. The presentation, titled APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as a Registrational Endpoint, was delivered by Veeral Sheth, M.D., M.B.A., a practicing retina specialist at University Retina, and Clinical Assistant Professor at the University of Illinois. 

Read more at globenewswire.com

Related news for (OCUP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.